Boosting the Body's Defenses Against Alzheimer's Disease and Brain Bleeds
Innate Immunity Stimulation Effects on Biomarkers, Cognition, and the Vascular Amyloid Proteome in a Squirrel Monkey Model of Sporadic CAA
This work explores how stimulating the body's natural immune system might help reduce problems seen in Alzheimer's disease and a related condition called cerebral amyloid angiopathy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11137736 on NIH RePORTER |
What this research studies
Researchers believe that problems with the body's immune system contribute to Alzheimer's disease. This project looks at whether activating a specific part of the immune system, called Toll-like receptor 9 (TLR9), can help immune cells work better to fight Alzheimer's disease changes. Previous work in mouse models showed that this approach could improve behavior and reduce disease markers. This current work uses squirrel monkeys, which naturally develop a condition similar to cerebral amyloid angiopathy (CAA) in humans, to see if this immune boost can be effective without causing side effects like those seen in some human trials.
Who could benefit from this research
Good fit: This foundational animal model work is not recruiting patients, but future clinical trials based on these findings would likely target individuals with Alzheimer's disease or cerebral amyloid angiopathy.
Not a fit: Patients without Alzheimer's disease or cerebral amyloid angiopathy would not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this approach could lead to new treatments for Alzheimer's disease and cerebral amyloid angiopathy that are both effective and safer for patients.
How similar studies have performed: Previous studies in mouse models have shown promising results with similar immune-boosting strategies, but this work aims to bridge the gap to human trials using a more relevant animal model.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Scholtzova, Henrieta — New York University School of Medicine
- Study coordinator: Scholtzova, Henrieta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.